GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future.
Sign Up to like & getrecommendations! Published in 2017 at "Current pharmaceutical design"
DOI: 10.2174/1381612823666170714141450
Abstract: GSK3 has gained a considerable attention of researchers in the late 1970s as an inevitable drug target to treat diabetes. Furthermore, it was found to have a key role in the development of diseases like… read more here.
Keywords: cancer neurodegeneration; gsk3; gsk3 inhibitors; diabetes cancer ... See more keywords
Meridianins and Lignarenone B as Potential GSK3β Inhibitors and Inductors of Structural Neuronal Plasticity
Sign Up to like & getrecommendations! Published in 2020 at "Biomolecules"
DOI: 10.3390/biom10040639
Abstract: Glycogen Synthase Kinase 3 (GSK3) is an essential protein, with a relevant role in many diseases such as diabetes, cancer and neurodegenerative disorders. Particularly, the isoform GSK3β is related to pathologies such as Alzheimer’s disease… read more here.
Keywords: meridianins lignarenone; neuronal plasticity; structural neuronal; gsk3 inhibitors ... See more keywords
Discovery of GSK3β Inhibitors through In Silico Prediction-and-Experiment Cycling Strategy, and Biological Evaluation
Sign Up to like & getrecommendations! Published in 2022 at "Molecules"
DOI: 10.3390/molecules27123825
Abstract: Direct inhibitors of glycogen synthase kinase 3β (GSK3β) have been investigated and reported for the past 20 years. In the search for novel scaffold inhibitors, 3000 compounds were selected through structure-based virtual screening (SBVS), and… read more here.
Keywords: gsk3 inhibitors; silico prediction; inhibitors silico; gsk3 ... See more keywords